Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of “Hold” by Analysts

Coherus Oncology, Inc. (NASDAQ:CHRS) has received an average rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.0167.

Several equities analysts have recently commented on the company. Oppenheimer started coverage on Coherus Oncology in a research note on Thursday. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a report on Wednesday, October 8th.

Institutional Trading of Coherus Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jefferies Financial Group Inc. boosted its holdings in shares of Coherus Oncology by 2.5% during the third quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after acquiring an additional 8,000 shares during the period. Corient Private Wealth LLC increased its holdings in shares of Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 10,000 shares during the period. Tejara Capital Ltd lifted its position in Coherus Oncology by 1.7% in the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after purchasing an additional 11,552 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Coherus Oncology by 108.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 13,832 shares during the last quarter. Finally, Quarry LP acquired a new position in Coherus Oncology during the 3rd quarter valued at about $26,000. 72.82% of the stock is owned by institutional investors.

Coherus Oncology Stock Down 3.0%

NASDAQ:CHRS traded down $0.05 on Thursday, reaching $1.59. The stock had a trading volume of 2,770,077 shares, compared to its average volume of 1,605,373. The company has a 50-day moving average of $1.37 and a 200 day moving average of $1.32. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The stock has a market cap of $192.18 million, a P/E ratio of 1.20 and a beta of 0.96. Coherus Oncology has a 12-month low of $0.71 and a 12-month high of $1.89.

Coherus Oncology (NASDAQ:CHRS) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $13.41 million. On average, research analysts predict that Coherus Oncology will post -1.05 earnings per share for the current year.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.